Sign in

CIK 0001640266

  • Accelerated filer
  • Smaller reporting company

Voyager Therapeutics, Inc.

Sign in to watch
Ticker
VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 857-259-5340
Business address
75 HAYDEN AVENUE, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-11-01 Carter Todd Alfred Chief Scientific Officer Grant or award +33,000 178,718
2026-11-01 Carter Todd Alfred Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +154,000 154,000
2026-11-01 Swartz Robin President Grant or award +68,250 267,988
2026-11-01 Swartz Robin President Grant or award · Stock Option (Right to Buy) +318,500 318,500
2026-06-09 SCANGOS GEORGE A Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 MACKEY CATHERINE J Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Hyman Steven Director Grant or award · Stock Option (Right to Buy) +30,000
2026-06-09 Vitale Nancy Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Higgins Michael J Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Onyia Jude Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 GERAGHTY JAMES A Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Colon Grace Director Grant or award · Stock Option (Right to Buy) +30,000
2026-06-09 PIERCE GLENN Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-04-02 Sandrock Alfred President and CEO Sale 10b5-1 −11,511 $3.87 $45K 472,549
2026-04-01 Shiferman Gregory L. SVP and General Counsel Grant or award +50,000 50,000
2026-02-24 Swartz Robin COO & CBO Sale 10b5-1 −6,458 $3.77 $24K 199,738
2026-02-24 Sandrock Alfred President and CEO Sale 10b5-1 −14,197 $3.79 $54K 484,060
2026-02-24 Jorgensen Nathan D. Chief Financial Officer Sale 10b5-1 −4,668 $3.77 $18K 151,416
2026-02-24 Carter Todd Alfred Chief Scientific Officer Sale 10b5-1 −4,174 $3.76 $16K 145,718
2026-02-18 Swartz Robin COO & CBO Sale 10b5-1 −3,882 $3.44 $13K 206,196

Page 1 of 7 · 130 trades